V
Vivia Oncology operates a high-throughput drug development pipeline focused on novel oncology targets and improving existing inhibitors. The company identifies and patents key oncogenic pathway inhibitors among clinically tested compounds. Simultaneously, they discover new small inhibitory molecules that demonstrate synergy with approved tyrosine kinase inhibitors (TKIs).
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Vivia Oncology operates a high-throughput drug development pipeline focused on novel oncology targets and improving existing inhibitors. The company identifies and patents key oncogenic pathway inhibitors among clinically tested compounds. Simultaneously, they discover new small inhibitory molecules that demonstrate synergy with approved tyrosine kinase inhibitors (TKIs).